Earnings Releases·Oct 29, 2026, 4:14 PM ET

Penumbra, Inc. — Third Quarter 2026 Earnings Summary

Revenue reached $410.1 million for the quarter, a 15.6% year-over-year increase, with net income of $42.3 million and diluted EPS of $1.07.
All major product lines drove growth, including global thrombectomy revenue up 18.1% to $279.2 million and U.S. VTE revenue up 26.0%.
The company will not provide full-year 2026 financial guidance or host a conference call due to the pending acquisition by Boston Scientific Corporation.
Significant acquisition-related risks remain, including potential delays in regulatory approvals, management distraction, and employee departures during the transaction pendency.
Balance sheet strengthened with cash and cash equivalents rising to $254.3 million, while total assets grew to $2.03 billion.